The inducible nitric oxide synthase promoter polymorphism does not confer susceptibility to systemic lupus erythematosus

Rheumatology

Volumn 42, Issue 1, 2003, Pages 113-116

  Lopez Nevot M A ^a   Ramal, L ^a   Jimenez Alonso J ^a   Martin J ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

Author keywords

Microsatellite polymorphism; Nitric oxide synthase; Systemic lupus erythematosus

Indexed keywords

MICROSATELLITE DNA; NITRIC OXIDE SYNTHASE;

ADOLESCENT; ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DINUCLEOTIDE REPEAT; DISEASE PREDISPOSITION; DNA FLANKING REGION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SPAIN; STATISTICAL SIGNIFICANCE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS);

EID: 0037257194     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keg044     Document Type: Article

References (22)

1. Bredt DS, Snyder SH. Nitric oxide: a physiologic messenger molecule. Annu Rev Biochem 1994;63:175-95.
2. Clancy RM, Amin AR, Abramson SB. The role of nitric oxide in inflammation and immunity. Arthritis Rheum 1998;41:1141-51.
3. G-monomethyl-L-arginine. J Exp Med 1994;179:651-60.
4. Huang FP, Feng GJ, Lindop G, Scott DI, Liew FGY. The role of interleukin 12 and nitric oxide in the development of spontaneous autoimmune disease in MRL/MP-lpr/lpr mice. J Exp Med 1996;183:1447-59.
5. Gilkeson G, Cannon C, Oates J, Reilly C, Goldman D, Petri M. Correlation of serum measures of nitric oxide production with lupus disease activity. J Rheumatol 1999; 26:318-24.
6. Wanchu A, Khullar M, Deodhar SD, Bambery P, Sud A. Nitric oxide synthesis is increased in patients with systemic lupus erythematosus. Rheumatol Int 1998;18:41-3.
7. Belmont HM, Levartovsky D, Goel A et al. Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:1810-6.
8. Nathan C. Inducible nitric oxide synthase: what difference does it make? J Clin Invest 1997;100:2417-23.
9. Kun JF, Mordmuller B, Lell B, Lehman LG, Luckner D, Kremsner PG. Polymorphism in promoter region of inducible nitric oxide synthase gene and protection against malaria. Lancet 1998;351:265-6.
10. Bellami R, Hill A. A bi-allelic tetranucleotide repeat in the promoter of the human inducible nitric-oxide synthase gene. Clin Genet 1997;52:192-3.
11. Xu W, Liu L, Emson PC, Harrington CR, Charles IG. Evolution of a homopurine-homopyrimidine pentanucleotide repeat sequence upstream of the human inducible nitric oxide synthase gene. Gene 1997;204:165-70.
12. n repeat of NOS2A in diabetic retinopathy. FASEB J 1999; 13:1825-32.
13. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
14. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, Committee on Prognosis Studies in SLE. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
15. Xu W, Humphries S, Tomita M et al. Survey of the allelic frequency of a NOS2A promoter microsatellite in human populations: assessment of the NOS2A gene and predisposition to infectious disease. Nitric Oxide 2000; 4:379-83.
16. Burgner D, Xu W, Rockett M et al. Inducible nitric oxide synthase polymorphism and fatal cerebral malaria. Lancet 1998;352:1193-4.
17. Levesque MC, Hobbs MR, Anstey NM et al. Nitric oxide synthase type 2 promoter polymorphisms, nitric oxide production, and disease severity in Tanzanian children with malaria. J Infect Dis 1999;180:1994-2002.
18. Johannesen J, Tarnow L, Parvinng HH, Nerup J, Pociot F. CCTTT-repeat polymorphism in the human NOS2-promoter confers low risk of diabetic nephropathy in type 1 diabetic patients. Diabetes Care 2000;23:560-2
19. Pascual M, López-Nevot MA, Cáliz R et al. Genetic determinants of rheumatoid arthritis: the inducible nitric oxide synthase (NOS2) gene promoter polymorphism. Genes Immun 2002;3:299-301.
20. Johannensen J, Pociot F, Kristiansen OP, Karlsen AE, Nerup J, DIEGG, DSGD. No evidence for linkage in the promoter region of the inducible nitric oxide synthase gene (NOS2) in a Danish type 1 diabetes population. Genes Immun 2000;1:362-6.
21. González-Crespo MR, Navarro JA, Arenas J, Martín-Mola E, de la Cruz J, Gómez-Reino JJ. Prospective study of serum and urinary nitrate levels in patients with systemic lupus erythematosus. Br J Rheumatol 1998; 37:972-7.
22. Lambaréne (G-954C), increased nitric oxide production and protection against malaria. J Infect Dis 2001;